About Solitary Fibrous Tumor
A solitary fibrous tumor (SFT) is a rare growth that starts in mesenchymal tissue, often in the lining of the lungs but can also form in areas like:
- Brain and spinal cord (central nervous system)
- Nasal and throat areas (upper respiratory tract)
- Eye socket (orbit of the eye)
- Thyroid gland
- Abdominal lining (peritoneum)
SFTs usually grow slowly and may not cause symptoms until they become large. They often have clear boundaries and are enclosed in a capsule. Most SFTs are not cancerous, but some can become aggressive or malignant. Diagnosing SFTs is tricky due to vague symptoms, requiring a healthcare professional’s evaluation and tissue testing for confirmation.
The exact cause of SFT is not fully understood, but it is believed to involve genetic mutations and abnormal growth signals. Here are the potential causes and risk factors associated with SFT:
Causes of SFT:
- Genetic Mutations: Changes in specific genes have been identified in some cases of SFT. These mutations can lead to uncontrolled cell growth and tumor formation.
- Abnormal Growth Signals: Dysregulation of growth factors and signaling pathways may contribute to the development of SFT.
The exact risk factors for solitary fibrous tumors (SFTs) are not well understood. However, a few possible factors include:
- Age: SFTs are more commonly diagnosed in middle-aged and older adults.
- Radiation exposure: Previous exposure to radiation might increase the risk.
- Genetic mutations: Abnormal changes in certain genes, such as the NAB2-STAT6 fusion gene, are linked to SFTs.
- Environmental factors: Long-term exposure to certain toxins or pollutants may play a role, though this is not well-established.
It's important to note that these factors are based on current understanding and research findings. As with any medical condition, individual cases may vary, and further research is needed to fully elucidate the causes and risk factors of SFT. If you have concerns about SFT or any other health condition, it's best to consult with a healthcare professional for personalized advice.
The most common early symptom of Solitary Fibrous Tumor (SFT) is spinal pain, which is experienced by 69% of patients. In some cases, spinal pain may be the only symptom present.
Other symptoms that may occur with later stages, progression, or higher severity of SFT include:
- Spinal cord compression: This can cause symptoms such as weakness, numbness, or tingling in the limbs, difficulty walking, and problems with coordination.
- Radicular compression: This involves compression of the nerves that branch out from the spinal cord and can lead to pain or deficits in specific areas of the body.
- Urinary dysfunction: In some cases, SFT can cause urinary problems such as difficulty urinating or incontinence.
It's important to note that these symptoms can vary depending on the location and size of the tumor. It's also worth mentioning that SFT is a rare condition and preoperative diagnosis is typically not obtained. If you experience any concerning symptoms or have any questions, it's best to consult with a healthcare professional for an accurate diagnosis and appropriate management.
To diagnose Solitary Fibrous Tumor (SFT), the following examinations, tests, and procedures are commonly performed:
- Medical history evaluation: The doctor will review your medical history to understand your symptoms and any risk factors.
- Physical examination: The doctor will perform a physical examination to check for any abnormalities or signs of SFT.
- Imaging studies: Various imaging tests may be conducted to visualize the tumor and assess its location and size. These may include:
- CT scan: Provides detailed cross-sectional images of the affected area.
- MRI: Uses magnetic fields and radio waves to create detailed images of the tumor.
- PET-CT or bone scan: Used to evaluate the spread of the tumor to other parts of the body.
- Biopsy: A tissue sample is taken from the tumor site using a core needle or incision biopsy. This sample is then examined under a microscope to confirm the diagnosis of SFT.
To determine the stage or severity of SFT, additional examinations, tests, and procedures may be performed:
- Histological analysis: The tissue sample obtained from the biopsy is analyzed by a pathologist to determine if the tumor is benign or malignant.
- Mitotic activity assessment: The number of mitotic figures (cell division) per high-power field is counted to assess tumor aggressiveness.
- Presence of necrosis or hemorrhage: The presence of necrosis (cell death) or hemorrhage (bleeding) within the tumor can indicate a more severe form of SFT.
- Surgical exploration: In some cases, surgery may be required to fully assess the extent and stage of the tumor.
It's important to consult with your healthcare professional for personalized advice regarding diagnostic examinations, tests, and procedures for SFT.
The goals of treatment for Solitary Fibrous Tumor (SFT) are to:
- Diagnose and treat: Surgical removal is the first step to confirm and treat SFTs, aiming for complete tumor removal despite challenges like bleeding or spinal cord involvement.
- Prevent recurrence: Surgery reduces the risk of recurrence, though SFTs can return on average after 5.8 years.
- Ensure safety: Surgery prioritizes patient safety and controls bleeding (hemostasis) to minimize risks and operative time.
- Manage advanced cases: Radiotherapy can shrink inoperable tumors or treat advanced recurrences, while targeted therapies like apatinib may help reduce tumor growth in progressive cases.
It is important to note that the available literature on adjuvant therapy for SFTs is limited, and further investigation is needed to determine its role in treatment.
To achieve these treatment goals, the following interventions may be recommended:
- Surgical removal: This is the primary treatment approach for SFTs and aims to remove the tumor completely.
- Radiotherapy: Used as adjuvant therapy after subtotal removal or for inoperable local disease, it can provide palliation and shrinkage.
- Targeted drug therapies: Drugs like apatinib have shown promise in reducing tumor density and may be considered for progressive SFTs.
It's essential to consult with a healthcare professional who can provide personalized advice based on your specific situation.